

Cereno Scientific announces block trade of warrants and receives subscription commitment

Cereno Scientific (XSAT: CRNO B) (“Cereno” or the “Company”) today announced that it has been brought to the Company’s attention that a block trade has been executed, where GU Ventures as well as members of the Company’s Board of Directors and management has sold warrants of series TO1 to an unnamed buyer. In connection with the transaction a subscription commitment for the exercise of warrants of series TO1 has been undertaken by the buyer.

The transaction involves 1,713,537 warrants of series TO1 and has been executed outside of the marketplace. The purpose of the transaction has been to allow for an investor to acquire shares in the Company and to achieve the best possible subscription rate during the subscription period for the warrants of series TO1.

The subscription commitment has been agreed in writing and no consideration is to be paid for the subscription commitment. The subscription commitment is not secured through bank guarantees, restricted funds, pledged assets or similar arrangements.

Further information about the warrants of series TO1 can be found on the Company’s website.

For further information, please contact:

Daniel Brodén, CFO

Phone: +46 768 66 77 87

Email: info@cerenoscientific.com

About Cereno Scientific AB

Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeAcetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. In addition, Cereno has two promising preclinical development programs named CS014 and CS585 targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.